JAK3 is an intracellular tyrosine kinase involved in cytokine and antibody receptor signaling. This kinase is frequently activated during the course of inflammatory autoimmune diseases. JAK3 is a member of the JAK family, together with JAK1, JAK2 and TIE2. It is downstream of the common g-chain of cytokine receptors to IL2, IL4, IL7, IL15, and IL21 in hematopoietic cells.
Screening for selective JAK3 inhibitors using the DynamixFit™ technology, Dynamix has identified a large number of novel, selective, small-molecule JAK3 inhibitors. These inhibitors demonstrate intra-JAK selectivity as well as a broad inter-kinase selectivity, and have excellent ADME properties. Furthermore, these compounds have shown potency in a range of immune related cell-based assays.
Dynamix is developing its highly selective JAK3 inhibitors for the treatment of multiple autoimmune disorders as well as for hematological malignancies.